PT  - JOURNAL ARTICLE
AU  - Mona Bafadhel
AU  - Rosa Faner
AU  - Camille Taillé
AU  - Richard E.K. Russell
AU  - Tobias Welte
AU  - Peter J. Barnes
AU  - Alvar Agustí
TI  - Inhaled corticosteroids for the treatment of COVID-19
AID  - 10.1183/16000617.0099-2022
DP  - 2022 Dec 31
TA  - European Respiratory Review
PG  - 220099
VI  - 31
IP  - 166
4099  - http://err.ersjournals.com/content/31/166/220099.short
4100  - http://err.ersjournals.com/content/31/166/220099.full
SO  - EUROPEAN RESPIRATORY REVIEW2022 Dec 31; 31
AB  - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused severe illness and mortality for millions worldwide. Despite the development, approval and rollout of vaccination programmes globally to prevent infection by SARS-CoV-2 and the development of coronavirus disease 2019 (COVID-19), treatments are still urgently needed to improve outcomes. Early in the pandemic it was observed that patients with pre-existing asthma or COPD were underrepresented among those with COVID-19. Evidence from clinical studies indicates that the inhaled corticosteroids (ICS) routinely taken for asthma and COPD could have had a protective role in preventing severe COVID-19 and, therefore, may be a promising treatment for COVID-19. This review summarises the evidence supporting the beneficial effects of ICS on outcomes in patients with COVID-19 and explores the potential protective mechanisms.Treatments are urgently needed to improve outcomes for patients with coronavirus disease 2019 (COVID-19) infection. This review summarises the evidence for the potential protective role of inhaled corticosteroids in preventing severe COVID-19 https://bit.ly/3yCAvfn